Advanced search×

The cytokine network in asthma and chronic obstructive pulmonary disease.

Peter J PJ Barnes

J Clin Invest 118(11):3546-56 (2008) PMID 18982161 PMCID 2575722

Asthma and chronic obstructive pulmonary disease (COPD) are very common inflammatory diseases of the airways. They both cause airway narrowing and are increasing in incidence throughout the world, imposing enormous burdens on health care. Cytokines play a key role in orchestrating the chronic inflammation and structural changes of the respiratory tract in both asthma and COPD and have become important targets for the development of new therapeutic strategies in these diseases.

DOI: 10.1172/JCI36130
Version: za2963e q8zaa q8zb9 q8zc1 q8zdd q8ze4 q8zfa q8zgf

Similar articles you may find interesting…

  1. Anesthesia in the patient with multiple drug allergies: are all allergies the same?
    Pascale P Dewachter, Claudie C Mouton-Faivre, ... David L DL Hepner

    Curr Opin Anaesthesiol 24(3):320-5 (2011) PMID 21494128

    Neuromuscular blocking agents (NMBAs) and antibiotics are the most common drugs triggering perioperative anaphylaxis. Quaternary ammonium ions have been suggested to be the allergenic determinant of NMBAs. Even though the 'pholcodine hypothesis' has been suggested to explain the occurrence of NMBA-i...
  2. [Drug-induced hypersensitivity syndrome--a literature review and the case report].
    Krzysztof K Gomułka, Danuta D Kuliczkowska, ... Bernard B Panaszek

    Pneumonol Alergol Pol 79(1):52-6 (2011) PMID 21190154

    We describe a case of a 72-years-old female who developed symptoms of drug-induced hypersensitivity syndrome after approximately 4 weeks of taking anticonvulsant (Amizepin) due to sensual axonal polyneuropathy. Withdrawal of drug and treatment with systemic corticosteroids caused clinical improvemen...
  3. Novel CRTH2 antagonists: a review of patents from 2006 to 2009.
    Trond Ulven and Evi Kostenis

    Expert Opin Ther Pat 20(11):1505-30 (2010) PMID 20946089

    We will see new CRTH2 antagonists reaching the market for the treatment of asthma, rhinitis, atopic dermatitis and/or COPD seems good....